Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
It was reported that verapamil is metabolized via hepatic microsomal cytochrome P450 (CYP) 3A4 and that naringin (a component of grapefruit juice) inhibits CYP3A4 in humans. Hence, after oral administration of verapamil, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of verapamil and the AUC(verapamil)/AUC(D-617 (a metabolite of verapamil)) ratio were significantly greater after oral grapefruit juice in humans. The aim of this study was to determine whether similar results could be obtained from rabbits. The pharmacokinetics of verapamil and one of its metabolites, norverapamil, were investigated after oral administration of verapamil at a dose of 9 mg/kg without or with oral naringin at a dose of 7.5 mg/kg in rabbits. With naringin, the AUC of verapamil was significantly greater (28.4 versus 18.4 microg min/ml). Although, the AUC values of norverapamil were not significantly different between groups without and with naringin, the AUC(verapamil)/AUC(norverapamil) ratio was considerably greater (1.49 versus 1.11) with naringin. The above data suggested that the metabolism of verapamil and the formation of norverapamil was inhibited by naringin possibly by inhibition of CYP3A in rabbits.
Kim
Hyoung J
HJ
College of Pharmacy, Chosun University, Gwangju, Republic of Korea.
Choi
Jun S
JS
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001711:Biotransformation; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D044950:Flavanones / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D011817:Rabbits; D014700:Verapamil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*
D002121:Calcium Channel Blockers; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D044950:Flavanones; C016904:norverapamil; D014700:Verapamil; D051544:Cytochrome P-450 CYP3A; C005274:naringin